Qinghai Spring Medicinal Resources Technology Co (SHSE:600381) 3-Year EBITDA Growth Rate : -56.90% (As of Sep. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Qinghai Spring Medicinal Resources Technology Co 3-Year EBITDA Growth Rate?

Qinghai Spring Medicinal Resources Technology Co's EBITDA per Share for the three months ended in Sep. 2024 was ¥-0.05.

During the past 3 years, the average EBITDA Per Share Growth Rate was -56.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Qinghai Spring Medicinal Resources Technology Co was 205.10% per year. The lowest was -56.90% per year. And the median was -12.50% per year.

Competitive Comparison of Qinghai Spring Medicinal Resources Technology Co's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Qinghai Spring Medicinal Resources Technology Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Qinghai Spring Medicinal Resources Technology Co's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Qinghai Spring Medicinal Resources Technology Co's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Qinghai Spring Medicinal Resources Technology Co's 3-Year EBITDA Growth Rate falls into.

Save Embed

;

Save Embed

;

Qinghai Spring Medicinal Resources Technology Co 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Qinghai Spring Medicinal Resources Technology Co (SHSE:600381) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Qinghai Spring Medicinal Resources Technology Co 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Qinghai Spring Medicinal Resources Technology Co's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Qinghai Spring Medicinal Resources Technology Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Qinghai Spring Medicinal Resources Technology Co Ltd (SHSE:600381) » Definitions » 3-Year EBITDA Growth Rate

Traded in Other Exchanges

N/A

Address

East New Road 1, Xining Economic and Technological Development Zone, Xining, CHN, 810007

Website

http://www.verygrass.com

Qinghai Spring Medicinal Resources Technology Co Ltd is a China-based company that principally engaged in the integrated development, utilization, production, sales, and consulting services of the natural advantageous resources on the Qinghai-Tibet plateau, as well as the development and utilization of other biological resources. The Company's main products are the cordyceps sinensis series products under the Verygrass brand, which includes cordyceps sinensis pure powder tablet, processed cordyceps sinensis, and raw cordyceps sinensis.

Executives

Xiao Rong	Director
Lu Yi Ping	Director

Qinghai Spring Medicinal Resources Technology Co Headlines

No Headlines